EICHORPublic-registry site landscape for NCT03207256, “Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials”, a Chronic Lymphocytic Leukemia study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03207256 (registry record) |
| Study title | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials |
| Official title | An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study. |
| Sponsor | TG Therapeutics, Inc. |
| Condition(s) | Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma |
| Phase | PHASE2 |
| Listed sites | 17 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03207256.
Eichor generates a preliminary site-risk snapshot for NCT03207256 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Chronic Lymphocytic Leukemia trials
More from TG Therapeutics, Inc.
← Eichor home · All tracked trials · Chronic Lymphocytic Leukemia studies · Weekly briefs
